Eyebot, a Boston, MA-based developer of rapid point-of-sale eye prescription technologies, raised $6M in Seed funding.
The round was led by AlleyCorp and Ubiquity Ventures with participation from Humba Ventures, Ravelin, Spacecadet and previous investors Baukunst and Village Global.
The company intends to use the funds to expand its product development activities, grow the team, and accelerate its expansion initiatives.
Led by Matthias Hofmann, PhD, Founder and CEO, Eyebot is a deep tech company which specializes in the development of self-serve, rapid vision testing technologies. Through its first product, a freestanding self-serve vision testing terminal, Eyebot technology delivers accurate eye prescriptions directly at the point-of-sale via a 90-second automated experience.
Eyebot has completed clinical studies involving hundreds of patients and validated its self-serve modality in several US cities. The company has orders from leading eyewear brands, has built a tele-doctor network of providers, and is planning to scale in 2025.
